RELIANCE vs SHUKRAPHAR: Stock Comparison

Head-to-head financial and trading comparison between Reliance Industries Limited (RELIANCE) and Shukra Pharmaceuticals Limited (SHUKRAPHAR) in the Cross-Sector Peers sector.

RELIANCE

NSE: RELIANCE
Reliance Industries Limited
₹1,170.30
1Y Return: -14.16%
52W High: ₹1,463.60
52W Low: ₹1,167.70
Annual Volatility: 21.69%
Check RELIANCE Trade Fees →

SHUKRAPHAR

NSE: SHUKRAPHAR
Shukra Pharmaceuticals Limited
₹66.94
1Y Return: +61.61%
52W High: ₹72.58
52W Low: ₹41.42
Annual Volatility: 64.68%
Check SHUKRAPHAR Trade Fees →

Key Metrics Comparison Table

MetricRELIANCESHUKRAPHAREdge / Winner
Current Market Price (CMP) ₹1,170.30 ₹66.94 —
1-Year Price Return -14.16% +61.61% SHUKRAPHAR (75.77% higher)
52-Week High ₹1,463.60 ₹72.58 —
52-Week Low ₹1,167.70 ₹41.42 —
30-Day Annualized Volatility 21.69% 64.68% RELIANCE (Steadier)
30-Day Average Daily Volume 13,199,026 6,592,919 RELIANCE (Higher Liquidity)
Statutory Cost to Trade ₹1 Lakh ₹118.50 ₹118.50 Identical statutory tariff

Frequently Asked Questions

Between RELIANCE and SHUKRAPHAR, which stock gave better returns over the last year?

SHUKRAPHAR has outperformed RELIANCE over the past 12 months with a gain of 61.61% compared to -14.16%.

Which stock is less volatile: RELIANCE or SHUKRAPHAR?

RELIANCE demonstrated lower price volatility (21.69% annualized) compared to SHUKRAPHAR (64.68%). Lower volatility generally indicates steadier price action during market downturns.

What is the statutory cost to buy ₹1,00,000 of RELIANCE vs SHUKRAPHAR?

Statutory exchange and government charges (STT, NSE turnover fees, SEBI fee, Stamp duty, and GST) are identical for delivery purchases of equal rupee value across both stocks, totaling approximately ₹118.50 on discount brokers offering zero delivery brokerage (like Zerodha or Dhan).

Are RELIANCE and SHUKRAPHAR direct sector competitors?

Yes, both companies operate within the Cross-Sector Peers sector in India and are actively tracked as sector peers by institutional and retail market participants.